| About
Pinnacle’s platform technology includes new chemical entities in the antibiotics, oncology, and pain management space. Additionally, Pinnacle is advancing novel and potent synergistic compounds for current antibiotic regimes to treat patients suffering from infections refractory to the current gold-standard. Our next generation approach to antimicrobial design is poised to yield superior medicines. Enabled by its comprehensive research, development and drug discovery activities, Pinnacle is pursuing therapeutics for several infectious disease indications including methicillin resistant Staphylococcus aureus (MRSA) and vancomycin resistant enterococci (VRE). Pinnacle is rapidly progressing its lead compounds from the research laboratory into clinical development. |